User:Mr. Ibrahem/Lorlatinib

Lorlatinib, sold under the brand name Lorbrena and Lorviqua, is a medication used to treat non-small cell lung cancer (NSCLC). Specifically it is used in anaplastic lymphoma kinase (ALK) positive cases that have failed other treatments. It is taken by mouth.

Common side effects are high cholesterol, high triglycerides, swelling, peripheral neuropathy, problems with memory, tiredness, weight gain, and joint pain. Other side effects may include liver problems, seizures, hallucinations, pneumonitis, and AV block. Use in pregnancy may harm the baby. It is a tyrosine kinase inhibitor of ALK and ROS1.

Lorlatinib was approved for medical use in the United States in 2018 and Europe in 2019. In the United Kingdom it costs the NHS about £5,300 a month as of 2021. This amount in the United States is about 18,500 USD.